Ujabb klinikai adatok a daganatos betegek anémiájának erythropoetinkezelésében. Az Amerikai Klinikai Onkológiai Társaság (ASCO) 2005. évi orlandói kongresszusán bemutatott fontosabb eredmények összefoglalása.

Translated title of the contribution: New clinical data on erythropoietin therapy of cancer patients with anemia. Summary of the major presentations at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, 2005

Research output: Contribution to journalArticle

Abstract

Anemia of patients with malignancy might have various reasons. No matter if its background is the underlying tumorous disease or chemo- and/or radiotherapy, it can cause fatigue, malaise, it certainly decreases the patients' quality of life and, furthermore, shortens their survival. Chronic hypoxia caused by anemia promotes tumor progression by several mechanisms e.g. by enhancing angioneogenesis by the production of VEGF. At the same time it decreases the efficacy of chemo- and radiotherapy. Therefore, prevention and/or correction of chemo/radiotherapy-induced anemia is a major goal of modern oncotherapy.

Original languageHungarian
Pages (from-to)251-254
Number of pages4
JournalMagyar Onkologia
Volume49
Issue number3
Publication statusPublished - 2005

Fingerprint

Erythropoietin
Anemia
Radiotherapy
Neoplasms
Vascular Endothelial Growth Factor A
Fatigue
Therapeutics
Quality of Life
Drug Therapy
Survival

ASJC Scopus subject areas

  • Cancer Research

Cite this

@article{497474250af74836ab0f4d5259e5d97e,
title = "Ujabb klinikai adatok a daganatos betegek an{\'e}mi{\'a}j{\'a}nak erythropoetinkezel{\'e}s{\'e}ben. Az Amerikai Klinikai Onkol{\'o}giai T{\'a}rsas{\'a}g (ASCO) 2005. {\'e}vi orland{\'o}i kongresszus{\'a}n bemutatott fontosabb eredm{\'e}nyek {\"o}sszefoglal{\'a}sa.",
abstract = "Anemia of patients with malignancy might have various reasons. No matter if its background is the underlying tumorous disease or chemo- and/or radiotherapy, it can cause fatigue, malaise, it certainly decreases the patients' quality of life and, furthermore, shortens their survival. Chronic hypoxia caused by anemia promotes tumor progression by several mechanisms e.g. by enhancing angioneogenesis by the production of VEGF. At the same time it decreases the efficacy of chemo- and radiotherapy. Therefore, prevention and/or correction of chemo/radiotherapy-induced anemia is a major goal of modern oncotherapy.",
author = "Istv{\'a}n L{\'a}ng",
year = "2005",
language = "Hungarian",
volume = "49",
pages = "251--254",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "3",

}

TY - JOUR

T1 - Ujabb klinikai adatok a daganatos betegek anémiájának erythropoetinkezelésében. Az Amerikai Klinikai Onkológiai Társaság (ASCO) 2005. évi orlandói kongresszusán bemutatott fontosabb eredmények összefoglalása.

AU - Láng, István

PY - 2005

Y1 - 2005

N2 - Anemia of patients with malignancy might have various reasons. No matter if its background is the underlying tumorous disease or chemo- and/or radiotherapy, it can cause fatigue, malaise, it certainly decreases the patients' quality of life and, furthermore, shortens their survival. Chronic hypoxia caused by anemia promotes tumor progression by several mechanisms e.g. by enhancing angioneogenesis by the production of VEGF. At the same time it decreases the efficacy of chemo- and radiotherapy. Therefore, prevention and/or correction of chemo/radiotherapy-induced anemia is a major goal of modern oncotherapy.

AB - Anemia of patients with malignancy might have various reasons. No matter if its background is the underlying tumorous disease or chemo- and/or radiotherapy, it can cause fatigue, malaise, it certainly decreases the patients' quality of life and, furthermore, shortens their survival. Chronic hypoxia caused by anemia promotes tumor progression by several mechanisms e.g. by enhancing angioneogenesis by the production of VEGF. At the same time it decreases the efficacy of chemo- and radiotherapy. Therefore, prevention and/or correction of chemo/radiotherapy-induced anemia is a major goal of modern oncotherapy.

UR - http://www.scopus.com/inward/record.url?scp=33644875489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644875489&partnerID=8YFLogxK

M3 - Article

C2 - 16249821

VL - 49

SP - 251

EP - 254

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 3

ER -